Table 1

Clinical-pathological characteristics of patients with CRC* and immunohistochemical staining for IL30 in their tumor samples

	No of patients	Percentages	IL30 immunostaining			P value
	No of patients	Percentages	IL30^+/+	IL30^+/-	IL30^-/-	P value
Sex
Female	56	46.32%	8 (14.39%)	42 (75.56%)	6 (10.79%)	0.823†
Male	64	53.68%	10 (15.52%)	45 (69.86%)	9 (13.97%)	0.823†
Total	120	100.00%	18 (15.00%)	87 (72.50%)	15 (12.50%)
Age
≤40	7	6.01%	1 (13.87%)	5 (69.33%)	1 (13.87%)	1‡
41–50	10	8.32%	1 (10.02%)	8 (80.13%)	1 (10.02%)	0.999‡
51–60	22	18.73%	4 (17.80%)	15 (66.74%)	3 (13.35%)	0.803‡
61–70	37	30.42%	5 (13.70%)	27 (73.96%)	5 (13.70%)	0.999†
71–80	33	27.31%	5 (15.26%)	24 (73.23%)	4 (12.21%)	0.999‡
≥81	11	9.21%	2 (18.10%)	8 (72.39%)	1 (9.05%)	0.881‡
Total	120	100.00%	18 (15.00%)	87 (72.50%)	15 (12.50%)
Clinical stage
Stage I	22	18.50%	3 (13.51%)	18 (81.08%)	1 (4.50%)	0.518‡
Stage II	45	37.19%	7 (15.69%)	30 (67.22%)	8 (17.93%)	0.375†
Stage III	35	29.22%	5 (14.26%)	26 (74.15%)	4 (11.41%)	0.999‡
Stage IV	18	15.09%	3 (16.57%)	13 (71.79%)	2 (11.04%)	1‡
Total	120	100.00%	18 (15.00%)	87 (72.50%)	15 (12.50%)
Molecular subtype
CMS1	19	16.20%	2 (10.29%)	15 (77.16%)	2 (10.29%)	0.921‡
CMS2	52	43.00%	8 (15.50%)	37 (71.71%)	7 (13.57%)	0.951†
CMS3	12	10.33%	2 (16.13%)	9 (72.60%)	1 (8.07%)	1‡
CMS4	24	20.03%	4 (16.64%)	16 (66.57%)	4 (16.64%)	0.708‡
Mixed	13	10.44%	2 (15.96%)	10 (79.82%)	1 (7.98%)	0.999‡
Total	120	100.00%	18 (15.00%)	87 (72.50%)	15 (12.50%)

*CRC patients had not received immunosuppressive treatments, or radiotherapy, and were free from immune system diseases.
†P values calculated using χ² test.
‡P values calculated using Fisher’s exact test.
CMS, consensus molecular subtypes; CRC, colorectal cancer.